Clinical Study

Ms200647_0046- Safety Study Of Bintrafusp Alfa In Combination With Other Anti-Cancer Therapies In Participants With Locally Advanced Or Advanced Cervical Cancer

Posted Date: May 5, 2021

  • Investigator: Amanda Jackson
  • Specialties: Cancer, Cervical Cancer, Gynecologic Oncology, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer. The primary outcome measured will be the incidence of Dose limiting toxicities.


Documented Evidence Of Cervical Adenocarcinoma, Squamous Cell Carcinoma, Or Adenosquamous Carcinoma, Ecog 0-1, Life Expectancy >12 Weeks, Adequate Hematological, Hepatic, Renal And Coagulation Function, No Previous Organ Transplant, No Significant Or Chronic Infection, No Active Central Nervous System (Cns) Metastasis, No Clinically Significant Cardiovascular/Cerebrovascular Disease, No Prior Cancer Treatment With Any Other Immunotherapy Or Checkpoint Inhibitors Or Any Other Immune-Modulating Monoclonal Antibody


Cervical Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.